Mouse TSPAN8 Protein, His Tag (MALS verified)
分子別名(Synonym)
CO-029,tetraspanin 8,TM4SF3,TM4SF3tspan-8,Transmembrane 4 superfamily member 3tetraspanin-8,TSPAN8,Tspan-8,Tumor-associated antigen CO-029
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Mouse TSPAN8 Protein, His Tag (TS8-M5249) is expressed from human 293 cells (HEK293). It contains AA Gly 106 - Asn 203 (Accession # Q8R3G9-1).
Predicted N-terminus: HiS
蛋白結(jié)構(gòu)(Molecular Characterization)

This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 12.8 kDa. The protein migrates as 15-19 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

背景(Background)
Tspan8是tetraspanin家族33個(gè)哺乳動(dòng)物成員中的1個(gè),由跨膜蛋白組成,這些蛋白橫向組織,與整合素等其他膜伴侶一起或與整合素一起形成“tetraspanin-web”。這些平臺(tái)在細(xì)胞內(nèi)發(fā)出信號(hào)以調(diào)節(jié)許多細(xì)胞過程:粘附、遷移、侵襲或存活Tspan8與許多類型的癌癥有關(guān)。據(jù)報(bào)道,在膠質(zhì)瘤和結(jié)直腸癌、食管癌、肝癌、胃癌和胰腺癌中存在過表達(dá)。Tspan8通過與膜伴侶如α6β4整合素蛋白激酶C(PKC)激活、E-鈣粘蛋白、EpCAM、claudin-7和CD44的結(jié)合來控制細(xì)胞和細(xì)胞-基質(zhì)相互作用,從而發(fā)揮促侵襲功能。此外,Tspan8可能是一個(gè)有前景的新治療靶點(diǎn),因?yàn)?/span>Tspan8特異性抗體已被證明可以降低細(xì)胞運(yùn)動(dòng),阻斷體內(nèi)腫瘤血管生成。
關(guān)鍵字: TSPAN8;TSPAN8蛋白;TSPAN8重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國、美國、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。